Advancements in urothelial carcinoma treatment – International Urology Cancer Summit
International Urology Cancer Summit shared a post on LinkedIn:
“Advancements in urothelial carcinoma treatment.
The latest NEJM study highlights the significant benefits of adjuvant pembrolizumab in improving disease-free survival for patients with high-risk muscle-invasive urothelial carcinoma post-surgery.
However, the question remains: should we delve deeper into subgroup analyses to refine patient selection and maximize the potential of adjuvant immunotherapy?
Let’s discuss how precision oncology can further enhance outcomes for patients in this challenging setting.
Thanks to the incredible team behind this work, including Andrea Apolo, Guru Sonpavde, Petros Grivas, Abhishek Tripathi, Suzanne Cole, Sandy Srinivas, Daniel Petrylak, Jeannie Hoffman-Censits, Alan Tan, Elad Sharon, Michael Morris and many more for pushing the boundaries of oncology research!”
“Really highlights PDL-1’s disappointment as a biomarker in urothelial carcinoma, as well as the clear difference between lower and upper tract tumours.”
More posts featuring International Urology Cancer Summit and Akash Maniam.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023